Sharon Ayd is Senior Vice President, Regulatory Affairs at 32 Biosciences, where she leads regulatory strategy supporting the advancement of CS-0003 toward human clinical development. She brings more than 35 years of leadership experience spanning strategic planning, operations, research and development, clinical development, and regulatory strategy within the biopharmaceutical industry.

Sharon has extensive experience in the development of small molecules, therapeutic proteins, biosimilars, and drug-device combination products across multiple therapeutic areas. As Founder and CEO of Ayd BioPharma Consulting Group, she has advised life sciences companies from nonclinical development through clinical development, regulatory approval, product launch, and lifecycle management.

Previously, Sharon served as Vice President of Innovation & Development at Fresenius Kabi, where she oversaw a substantial sterile injectable development portfolio for North America. She also held global leadership roles at Hospira, now part of Pfizer, and senior positions at emerging biotechnology companies including Advanced Life Sciences and Pinnacle Biologics. Across her career, her work has contributed to numerous global drug applications and regulatory approvals.

At 32 Biosciences, Sharon is focused on the regulatory strategy, IND-enabling pathway, agency interactions, and clinical-development planning required to advance CS-0003 from preclinical development into human studies.